Pyrimidineamines as angiogenesis modulators.

Details for Australian Patent Application No. 2002246723 (hide)

International Classifications

Event Publications

6 February 2003 Application Open to Public Inspection

Published as AU-B-2002246723

14 July 2005 Application Accepted

Published as AU-B-2002246723

10 November 2005 Standard Patent Sealed

26 August 2010 Extension of Term of Standard Patents

Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 30 Jun 2010 For the goods VOTRIENT pazopanib

2 September 2010 Extension of Term of Standard Patents

Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 30 Jun 2010 For the goods VOTRIENT pazopanib Address for service in Australia: Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

27 January 2011 Extension granted

Glaxo Group Limited Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Extensions granted The earliest first regulatory approval date provided by the patentee 30 Jun 2010 For the goods VOTRIENT pazopanib Extension of Term of patent pursuant to Section 77 expires on 30 Jun 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.